Factors associated with high-flow therapy failure in COVID-19-related acute hypoxemic respiratory failure: A prospective single-centre cohort study.

Authors

Toni Marín, Marina Galdeano, Roxana Chirinos, Agnés Hernández, Esther Roca, Adriana Martín, Andrea Garcia, Leire Mendiluce, Carmen Fernández, Cristian Tebé, Ignasi Garcia-Olivé, Roger Paredes, Antoni Rosell, Irene Aldás

Published in

Enfermedades infecciosas y microbiologia clinica (English ed.). Pages 503293. Oct 16, 2026. Epub Oct 16, 2026.

Abstract

The optimal selection of non-invasive respiratory support for patients with COVID-19-related acute hypoxemic respiratory failure remains uncertain. High-flow therapy (HFT) is frequently used as initial support, but early identification of patients at risk of escalation is clinically relevant. We evaluated clinical and laboratory variables associated with escalation from HFT to non-invasive positive-pressure ventilation (NPPV).
We conducted a prospective single-centre cohort study including 139 consecutive patients initiated on HFT in a respiratory intermediate care unit. The primary outcome was HFT failure, defined as escalation from HFT to NPPV. Time to HFT failure was analysed from HFT initiation using cause-specific Cox regression; successful HFT withdrawal without escalation was treated as censoring. A parsimonious adjusted model included age, time from symptom onset to HFT initiation, baseline PaO₂/FiO₂ ratio, and lactate dehydrogenase (LDH). Logistic regression and a supplementary bicarbonate model were used as sensitivity analyses.
Seventy-two of 139 patients (51.8%) required escalation to NPPV. Seventeen escalations were recorded on day 0 and 44 of 72 failures (61.1%) occurred by day 1. In the adjusted Cox model, higher LDH levels were associated with an increased hazard of escalation (adjusted hazard ratio [aHR] per 100U/L, 1.33; 95% confidence interval [CI], 1.06-1.66; p=0.014), whereas higher baseline PaO₂/FiO₂ ratios were associated with a lower hazard (aHR per 25mmHg, 0.78; 95% CI, 0.67-0.90; p=0.001). A longer interval from symptom onset to HFT initiation was also associated with a lower hazard of escalation (aHR per day, 0.93; 95% CI, 0.86-0.99; p=0.033). In a supplementary sensitivity model, higher arterial bicarbonate levels were associated with a lower hazard of escalation (aHR per 3mmol/L, 0.81; 95% CI, 0.66-0.99; p=0.039).
In this prospective single-centre cohort, LDH and baseline PaO₂/FiO₂ were associated with escalation from HFT to NPPV after adjustment. Arterial bicarbonate showed a supportive exploratory signal in sensitivity analysis. These findings require external validation before incorporation into treatment-selection algorithms.

PMID:
42888091
Bibliographic data and abstract were imported from PubMed on 17 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.